SCHEMBL23150461

SCHEMBL23150461

CCCCCn1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc21

nearest known ligand 0.73

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MTOR P42345 20/20 0.73
HDAC1 Q13547 6/20 0.73
HDAC3 O15379 2/20 0.73
HDAC2 Q92769 2/20 0.73
HDAC8 Q9BY41 2/20 0.73
HDAC6 Q9UBN7 2/20 0.73
PIK3CA P42336 8/20 0.69
PIK3CD O00329 6/20 0.69
PIK3CG P48736 6/20 0.69
PRKDC P78527 3/20 0.69
DDR1 Q08345 3/20 0.69
PIK3CB P42338 5/20 0.68
ABL1 P00519 2/20 0.68
RICTOR Q6R327 3/20 0.67
RPTOR Q8N122 3/20 0.67
MAPKAP1 Q9BPZ7 3/20 0.67
MLST8 Q9BVC4 3/20 0.67
PIK3C3 Q8NEB9 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23251652 0.97 MTOR (0.71) MTORHDAC1HDAC3HDAC2HDAC8
SCHEMBL19283020 0.92 MTOR (0.75) MTORHDAC1HDAC3HDAC2HDAC8
SCHEMBL30381095 0.91 MTOR (0.74) MTORHDAC1HDAC3HDAC2HDAC8
SCHEMBL20552603 0.91 MTOR (0.74) MTORHDAC1HDAC3HDAC2HDAC8
SCHEMBL20553596 0.89 MTOR (0.75) MTORHDAC1HDAC3HDAC2HDAC8
SCHEMBL29669811 0.89 MTOR (0.75) MTORHDAC1HDAC3HDAC2HDAC8
SCHEMBL20553395 0.89 MTOR (0.71) MTORHDAC1HDAC3HDAC2HDAC8
SCHEMBL30880103 0.89 MTOR (0.75) MTORHDAC1HDAC3HDAC2HDAC8
SCHEMBL29201811 0.89 MTOR (0.75) MTORHDAC1HDAC3HDAC2HDAC8
SCHEMBL19282991 0.87 MTOR (0.82) MTORHDAC1HDAC3HDAC2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230093861-A1 RAPAMYCIN ANALOGS AS MTOR INHIBITORS Revolution Medicines, Inc. 2023-03-30 US disclosed
US-20210094975-A1 RAPAMYCIN ANALOGS AS MTOR INHIBITORS Revolution Medicines, Inc. 2021-04-01 US disclosed
CN-110770243-A Rapamycin analogs as MTOR inhibitors 锐新医药公司 2020-02-07 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230093861-A1 RAPAMYCIN ANALOGS AS MTOR INHIBITORS MTOR, RICTOR, RPTOR MTOR 1/4885HDAC1 516/4885HDAC3 1131/4885
US-20210094975-A1 RAPAMYCIN ANALOGS AS MTOR INHIBITORS MTOR, RICTOR, RPTOR MTOR 1/4885HDAC1 516/4885HDAC3 1131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.